{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T14:23:08.810902",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 119,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "survival",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST)",
        "progression-free survivorship",
        "perioperative mortality",
        "treatment-related mortality",
        "death"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "objective response rate (ORR)",
        "tumor response rate",
        "tumour response rate",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "response (CR, PR mRECIST)",
        "imaging response (mRECIST)",
        "partial response (PR)",
        "partial response (radiological, independently assessed)",
        "partial response",
        "complete response (CR)",
        "complete remission",
        "minor response (radiological, independently assessed; reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (radiological, independently assessed; for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "local control",
        "tumor reduction",
        "objective tumour response"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time to radiological disease progression",
        "progression",
        "disease progression",
        "reduction of progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to response",
        "duration of response (DoR)",
        "duration of response (time from partial or complete response to disease progression or exit)",
        "time to quality of life impairment (EORTC QLQ-C30)",
        "time to quality of life impairment (EORTC QLQ-HCC18)",
        "time to quality of life impairment (EORTC QLQ-C30 functional role subscale)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "time to deterioration",
        "disease recurrence",
        "recurrence",
        "tumour relapse",
        "disease recurrence",
        "bridging therapy",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (CTCAE v5.0)",
        "adverse events (Grade ≥ 3)",
        "grade 3 adverse events",
        "grade 4 adverse events",
        "treatment-emergent adverse events (TEAE)",
        "treatment-emergent adverse events (TEAEs)",
        "adverse reactions (general)",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity",
        "toxicity",
        "side-effects (biopsy)",
        "complications",
        "complication incidence",
        "post-treatment complications",
        "serious adverse events",
        "serious complications",
        "significant haemorrhagic events",
        "haemorrhagic events",
        "bleeding",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "secondary cancer",
        "infections",
        "sepsis",
        "infusion reactions",
        "gastrointestinal disorders",
        "intestinal failure",
        "hepatic encephalopathy",
        "hepatic encephalopathy (grade > 1 on the New Haven criteria)",
        "hepatic insufficiency",
        "liver disorders",
        "liver failure",
        "hepatotoxicity",
        "renal events",
        "renal failure",
        "proteinuria",
        "hypertension",
        "hypertension (grade 3/4)",
        "hypothyroidism",
        "hyperthyroidism",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hyperkeratosis",
        "increased ALT activity",
        "increased amylase",
        "increased lipase",
        "transient increase in transaminases",
        "alopecia",
        "rash",
        "skin rash",
        "skin desquamation",
        "desquamation",
        "dry skin",
        "erythema",
        "pruritus",
        "dermatitis exfoliative",
        "acne",
        "folliculitis",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "hand feeding reactions (grade 3/4)",
        "dysphonia",
        "dysgeusia",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro oesophageal reflux disease",
        "nausea",
        "vomiting",
        "diarrhoea",
        "constipation",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "asthenia",
        "decreased appetite",
        "loss of appetite",
        "anorexia",
        "weight loss",
        "decreased weight",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "cough",
        "dyspnoea",
        "shortness of breath",
        "pleural effusion",
        "lymphoedema (grade 3/4)",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "haemorrhage",
        "arterial thromboembolic events",
        "thromboembolic events",
        "cerebral vascular accident",
        "cardiovascular arrest",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "sudden death",
        "death",
        "depression",
        "peripheral sensory neuropathy",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "erectile dysfunction",
        "influenza like illness"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "perioperative mortality",
        "mortality",
        "morbidity"
      ],
      "discontinuations": [
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "EQ-5D visual analogue scale",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "health status (EQ-5D visual analogue scale)",
        "global health status (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "overall quality of life (measured with a validated and reliable instrument)",
        "quality of life weights"
      ],
      "functional_status": [
        "physical complaints",
        "psychosocial complaints",
        "emotional complaints",
        "cognitive complaints",
        "behavioural complaints",
        "social complaints",
        "spiritual complaints"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "nutrition",
        "body image",
        "distress",
        "overall quality of life",
        "health-related quality of life (HRQoL)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "time to quality of life impairment (EORTC QLQ-C30)",
        "time to quality of life impairment (EORTC QLQ-HCC18)",
        "time to quality of life impairment (EORTC QLQ-C30 functional role subscale)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness",
        "cost-effectiveness analysis",
        "incremental cost-effectiveness ratio (ICER)",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis",
        "costs"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "number needed to harm (NNH)",
        "number needed to treat (NNT)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "prognosis (BCLC staging system)",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "local control rates",
        "tumor reduction",
        "tumour seeding",
        "side-effects (biopsy)",
        "diagnosis (multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced US)",
        "pathological examination",
        "immunohistochemistry markers (diagnosis, prognosis, subtypes)",
        "immunohistochemical confirmation",
        "genetic tests (metabolic diseases)",
        "genetic diagnosis",
        "molecular classification (driver gene mutations)",
        "histological and prognostic parameters",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "bridging therapy",
        "undesirable effects",
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "intraoperative complications",
        "postoperative softening",
        "gallbladder abscess",
        "varicose vein bleeding",
        "ascites"
      ],
      "biomarkers": [
        "plasma pharmacokinetics parameters",
        "pharmacokinetic/pharmacodynamic relationship",
        "pharmacokinetic parameters",
        "sustained virological response",
        "liver function",
        "comorbidities"
      ]
    }
  }
}